US OptionsDetailed Quotes

AUTL250516C500

Watchlist

0.00
0.000.00%

15min DelayClose Apr 25 09:30 ET

0.00High0.00Low

Autolus Therapeutics Stock Discussion

Teddy123

4 hours ago

Pharmaceutical industry analysis

$Autolus Therapeutics (AUTL.US)$
First regulatory approval validates Autolus' technology platform and establishes commercial pathway, though NICE approval remains critical next step.
This MHRA conditional authorization represents a transformative milestone for Autolus Therapeutics, validating both their lead product and underlying technology platform. As the company's first regulatory approval, it establishes Autolus as an emerging commercial-stage biopharmaceutic...

Teddy123

4 hours ago

Oncology/Biotech Analysis

$Autolus Therapeutics (AUTL.US)$
MHRA approval of AUCATZYL for r/r B-ALL represents significant treatment advance with impressive 76.6% response rate and manageable safety profile.
The MHRA's conditional authorization of AUCATZYL marks a critical advancement for adult patients with r/r B-ALL, a disease with historically poor outcomes. The FELIX study results are compelling, showing a 76.6% complete response rate in the pivotal cohort, with 21.2 months median response dur...

Teddy123

4 hours ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leuke

$Autolus Therapeutics (AUTL.US)$
Revolutionary Leukemia Treatment: Autolus's CAR-T Therapy Secures First-Ever UK Approval with 77% Success Rate

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leuke$

Trytosaveabit

Jan 17 20:24

watching for possible catalyst outadis! Hehehe

$Autolus Therapeutics (AUTL.US)$ Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes! February 12 to 15, 2025

Jaguar8

Dec 10, 2024 08:42

NEWS

$Autolus Therapeutics (AUTL.US)$
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...

Trytosaveabit

Dec 10, 2024 08:36

Watching

$Autolus Therapeutics (AUTL.US)$ Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 6 to 8 PM pst 12/9/24!
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE